The Impact of Chemo-Sensitivity on Surgical Resection in MYCN-Amplified Neuroblastoma

被引：0
|
作者：
Chui, C. H. [1 ]
机构：
[1] Surg Ctr Children Pte Ltd, Surg Oncol, Singapore, Singapore
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IPSO23 SIO
引用
收藏
页码：S86 / S86
页数：1
相关论文
共 50 条
  • [41] The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo
    Faisal, Amir
    Vaughan, Lynsey
    Bavetsias, Vassilios
    Sun, Chongbo
    Atrash, Butrus
    Avery, Sian
    Jamin, Yann
    Robinson, Simon P.
    Workman, Paul
    Blagg, Julian
    Raynaud, Florence I.
    Eccles, Suzanne A.
    Chesler, Louis
    Linardopoulos, Spiros
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (11) : 2115 - 2123
  • [42] Downregulation of BORIS/CTCFL leads to ROS-dependent cellular senescence and drug sensitivity in MYCN-amplified neuroblastoma
    Rao, Garikapati Koteswara
    Makani, Venkata Krishna Kanth
    Mendonza, Jolly Janette
    Edathara, Prajitha Mohandas
    Patel, Nibedita
    Ramakrishna, Maresha
    Cilamkoti, Priyanka
    Phukon, Jayashree Chiring
    Jose, Jedy
    Bhadra, Utpal
    Bhadra, Manika Pal
    FEBS JOURNAL, 2022, 289 (10) : 2915 - 2934
  • [43] Aurora-A stabilizes N-myc protein in MYCN-amplified neuroblastoma
    Berwanger, B.
    Otto, T.
    Horn, S.
    Schuettstrumpf, L.
    Kenney, A.
    Eilers, U.
    Eggert, A.
    Christiansen, H.
    Eilers, M.
    KLINISCHE PADIATRIE, 2008, 220 (03): : 198 - 198
  • [44] EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma
    Durbin, Adam D.
    Wang, Tingjian
    Wimalasena, Virangika K.
    Zimmerman, Mark W.
    Li, Deyao
    Dharia, Neekesh, V
    Mariani, Luca
    Shendy, Noha A. M.
    Nance, Stephanie
    Patel, Anand G.
    Shao, Ying
    Mundada, Maya
    Maxham, Lily
    Park, Paul M. C.
    Sigua, Logan H.
    Morita, Ken
    Conway, Amy Saur
    Robichaud, Amanda L.
    Perez-Atayde, Antonio R.
    Bikowitz, Melissa J.
    Quinn, Taylor R.
    Wiest, Olaf
    Easton, John
    Schonbrunn, Ernst
    Bulyk, Martha L.
    Abraham, Brian J.
    Stegmaier, Kimberly
    Look, A. Thomas
    Qi, Jun
    CANCER DISCOVERY, 2022, 12 (03) : 730 - 751
  • [45] Reversing the HDAC-inhibitor mediated metabolic escape in MYCN-amplified neuroblastoma
    Bishayee, Kausik
    Nazim, Uddin Md.
    Kumar, Vijay
    Kang, Jieun
    Kim, Jaebong
    Huh, Sung-Oh
    Sadra, Ali
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 150
  • [46] Serine-glycine-one-carbon metabolism: vulnerabilities in MYCN-amplified neuroblastoma
    Zhao, Erhu
    Hou, Jianbing
    Cui, Hongjuan
    ONCOGENESIS, 2020, 9 (02)
  • [47] Genetic variation associated with childhood and adult stature and risk of MYCN-amplified neuroblastoma
    Semmes, Eleanor C.
    Shen, Erica
    Cohen, Jennifer L.
    Zhang, Chenan
    Wei, Qingyi
    Hurst, Jillian H.
    Walsh, Kyle M.
    CANCER MEDICINE, 2020, 9 (21): : 8216 - 8225
  • [48] Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma
    Hallett, Robin M.
    Seong, Alex B. K.
    Kaplan, David R.
    Irwin, Meredith S.
    MOLECULAR ONCOLOGY, 2016, 10 (09) : 1461 - 1472
  • [49] MTHFD1 regulates the NADPH redox homeostasis in MYCN-amplified neuroblastoma
    Jinqiu Guan
    Mengzhen Li
    Yi Wang
    Yu Zhang
    Yi Que
    Suying Lu
    Juan Wang
    Jia Zhu
    Junting Huang
    Zijun Zhen
    Feifei Sun
    Mengjia Song
    Yizhuo Zhang
    Cell Death & Disease, 15
  • [50] MTHFD1 regulates the NADPH redox homeostasis in MYCN-amplified neuroblastoma
    Guan, Jinqiu
    Li, Mengzhen
    Wang, Yi
    Zhang, Yu
    Que, Yi
    Lu, Suying
    Wang, Juan
    Zhu, Jia
    Huang, Junting
    Zhen, Zijun
    Sun, Feifei
    Song, Mengjia
    Zhang, Yizhuo
    CELL DEATH & DISEASE, 2024, 15 (02)
12345